1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

Can New US FDA Commissioner Makary Calm Agency During Turbulent Times?

 
• By Sarah Karlin-Smith

Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.

person in a crowd holding sign that reads "America is great because of science"
FDA stakeholders are urging newly confirmed Commissioner Martin Makary to stand up for the agency's long-held scientific standards. (Shutterstock)
Key Takeaways
  • Stakeholders are closely watching newly confirmed US FDA Commissioner Martin Makary to see if he sides with the Trump Administration's disruption of federal agencies or tries to restore more typical FDA operations.
  • Many FDA stakeholder groups hope Makary will uphold the agency's rigorous scientific standards.
  • However, Makary may have trouble standing up for strong science on some topics, given his bosses in the administration.

When newly confirmed US Food and Drug Administration Commissioner Martin Makary enters the halls of a newly-crowded White Oak on 27 March, all eyes will be watching for whether he...

The Senate voted 56-44 on 25 March to confirm Makary, including all Republicans and three Democrats. He was sworn in by Health and Human Services Secretary Robert F. Kennedy Jr....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

US FDA Punts On New COVID-19 Framework’s Impact On Fall Shots

 
• By Sarah Karlin-Smith

The FDA’s advisors split on whether to update COVID-19 vaccines for the fall. The agency refused to discuss the impact of the new vaccine framework on availability.

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 
• By Derrick Gingery

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

Legal, Process Problems May Plague New US FDA COVID-19 Vaccine Policy

 
• By Sarah Karlin-Smith

The FDA may have violated laws and regulations along with many norms in how it released its planned changes for COVID-19 vaccine approvals.

US FDA COVID-19 Booster Strategy May Not Be As Controversial As It Seems

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s call for placebo-controlled trials to confirm the efficacy of COVID-19 boosters is drawing a lot of criticism, but former Commissioner Robert Califf also supported the idea.

More from Geography

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.